Clinical Trials Using Exemestane
Clinical trials are research studies that involve people. The clinical trials on this list are studying Exemestane. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.
Location: 30 locations
Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+ / HER2- Advanced Breast Cancer
This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4 / 6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI) .
Location: 20 locations
Fulvestrant or Exemestane with or without Ribociclib in Patients with Recurrent, Unresectable, or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
This randomized, phase II trial studies how well fulvestrant or exemestane with or without ribociclib works in treating patients with hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer that has progressed after treatment with an aromatase inhibitor or cyclin-dependent kinase 4 / 6 inhibitor (recurrent), cannot be removed by surgery (unresectable), or has spread to other parts of the body (metastatic). Hormone therapy using fulvestrant or exemestane may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving fulvestrant or exemestane with ribociclib may be an effective treatment for patients with breast cancer.
Location: 15 locations
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients with Bone Metastasis
This phase II trial studies how well radiation therapy given with standard care palbociclib and hormone therapy work in treating patients with breast cancer that has spread from one part of the body to the bone (bone metastasis). Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Antihormone therapy, such as fulvestrant, letrozole, anastrozole, exemestane, or tamoxifen, may lessen the amount of estrogen made by the body. Giving radiation therapy, palbociclib, and hormone therapy may work better in treating breast cancer patients with bone metastasis.
Location: 10 locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)
Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: - To compare the overall survival in the 2 treatment arms - To assess the objective response rate in the 2 treatment arms. - To evaluate the disease control rate in the 2 treatment arms. - To evaluate the clinical benefit rate in the 2 treatment arms. - To evaluate the duration of response in the 2 treatment arms. - To evaluate the PFS according to the estrogen receptor 1 gene (ESR1) mutation status in the 2 treatment arms. - To evaluate the pharmacokinetics of SAR439859 as single agent. - To evaluate health related quality of life in the 2 treatment arms. - To compare the overall safety profile in the 2 treatment arms.
Location: 8 locations
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
This study is designed to evaluate the efficacy, safety, and pharmacokinetics of several immunotherapy-based combination treatments in participants with inoperable locally advanced or metastatic HR-positive, HER2-negative breast cancer who have progressed during or following treatment with a cyclin-dependent kinase (CDK) 4 / 6 inhibitor in the first- or second-line setting, such as palbociclib, ribociclib, or abemaciclib. The study will be performed in two stages. During Stage 1, participants will be randomized to fulvestrant (control) or an atezolizumab-containing doublet or triplet combination. Those who experience disease progression, loss of clinical benefit, or unacceptable toxicity may be eligible to receive a new triplet combination treatment in Stage 2 until loss of clinical benefit or unacceptable toxicity. New treatment arms may be added and / or existing treatment arms may be closed during the course of the study on the basis of ongoing clinical efficacy and safety as well as the current treatments available.
Location: 7 locations
Fulvestrant and Palbociclib in Treating Older Patients with Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
This phase II trial studies how well fulvestrant and palbociclib works in treating older patients with breast cancer that responds to hormone treatment (hormone responsive) that cannot be removed by surgery. Estrogen can cause the growth of estrogen-receptor-positive breast cancer cells. Hormone therapy using fulvestrant may fight estrogen-receptor-positive breast cancer by blocking the use of estrogen by the tumor cells. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving fulvestrant together with palbociclib may be an effective treatment for hormone responsive breast cancer.
Location: 3 locations
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
The main objective of the trial is to assess the anti-tumor activity of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+ / HER2- advanced or metastatic breast cancer and non-visceral disease.
Location: 3 locations
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
Location: 4 locations
Ipatasertib with Aromatase Inhibitor, Fulvestrant, and / or Palbociclib in Treating Patients with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
This phase Ib trial studies the side effects and best dose of ipatasertib when given together with aromatase inhibitor (letrozole, anastrozole, or exemestane), fulvestrant, and / or palbociclib in treating patients with hormone receptor positive, HER2 negative breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). Stopping (inhibiting) an enzyme called Akt in tumor cells may stop cancer resistance to standard of care treatment. Ipatasertib is a type of inhibitor that may stop the growth of tumor cells by inhibiting Akt. Through the different combinations of ipatasertib and the standard of care drugs, the chance of cancer cells becoming resistant to the standard of care drugs may decrease, causing cancer cells to stop growing and spreading.
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Durvalumab and Aromatase Inhibitor before Surgery in Treating Postmenopausal Patients with Hormone-Receptor-Positive Breast Cancer
This phase II trial studies how well durvalumab and anastrozole (or other aromatase inhibitors) work when given before surgery in treating postmenopausal patients with hormone-receptor-positive breast cancer. Immunotherapy with monoclonal antibodies such as durvalumab may help the body’s immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Aromatase inhibitors, such as anastrozole, are hormonal blockers that are used in standard of care treatment of hormone receptor-positive breast cancer. This study may help find out how well durvalumab and anastrozole work when given before surgery in treating postmenopausal patients with hormone-receptor-positive breast cancer.
Location: Moffitt Cancer Center, Tampa, Florida
Talimogene Laherparepvec with Chemotherapy or Endocrine Therapy in Treating Patients with Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer
This phase Ib trials studies the side effects and how well talimogene laherparepvec works when given together with chemotherapy or endocrine therapy in treating patients with breast cancer that does not express the human epidermal growth factor receptor 2 (HER2) protein and has spread to other places in the body (metastatic), cannot be removed by surgery (unresectable), or has come back (recurrent). Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them. Chemotherapy drugs, such as nab-paclitaxel, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Estrogen can cause the growth of breast cancer cells. Drugs used as endocrine therapy, such as letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, may lessen the amount of estrogen made by the body or may may stop the growth of tumor cells by blocking estrogen from connecting to the cancer cells. Giving talimogene laherparepvec with chemotherapy or endocrine therapy may work better in treating patients with HER2-negative breast cancer.
Location: UCSF Medical Center-Mount Zion, San Francisco, California
Exemestane in Treating Post-menopausal Patients with Recurrent or Advanced Non-small Cell Lung Cancer
This phase II trial studies how well exemestane works in treating post-menopausal patients with non-small cell lung cancer that has come back (recurrent) or that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Exemestane blocks an enzyme that helps create estrogen. It has been used in treating breast cancer and may also be effective in treating advanced lung cancer while causing fewer side effects than traditional chemotherapy.
Location: University of Minnesota / Masonic Cancer Center, Minneapolis, Minnesota
Alternating Estradiol and Aromatase Inhibitor Therapies for the Treatment of ER+ / HER2- Advanced or Metastatic Breast Cancer, POLLY Study
This phase II trial studies how well alternating estradiol with an aromatase inhibitor (anti-estrogen therapy) works for the treatment of estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer that has spread to other places in the body (advanced or metastatic). Estradiol is an estrogen hormone that naturally occurs in humans. Estradiol is used for the treatment of symptoms of breast and prostate cancers. Aromatase inhibitors, such as letrozole, anastrozole, or exemestane, prevent the formation of estradiol by interfering with the aromatase enzyme. Aromatase inhibitors are often used as a type of therapy for post-menopausal women who have ER+ breast cancer. Alternating estradiol and with an aromatase inhibitors may work better than existing methods in treating patients with breast cancer.
Location: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Exemestane in Treating Patients with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
This pilot phase IIa trial studies how well exemestane works in treating patients with complex atypical hyperplasia of the endometrium / endometrial intraepithelial neoplasia or low grade endometrial cancer. Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 3 locations
Effects of Short-Term Hormone Therapy before Surgery on Gene Profiles in Patients with Stage I-III Breast Cancer
This phase IV trial investigates the effects of short-term hormonal therapy (letrozole, exemestane or tamoxifen) before surgery on how genes are expressed (gene profiles) in patients with stage I-III breast cancer. Letrozole and exemestane lower the amount of estrogen made by the body. This may stop the growth of tumor cells that need estrogen to grow Tamoxifen may help fight breast cancer by blocking the use of estrogen by the tumor cells. Information gained from this study may help researchers in advancing the individualized care to patients with breast cancer.
Location: 2 locations